Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications
Authors
Keywords
Angiogenesis, Heparanase, NADPH oxidase, Lysyl oxidase, Angiotensin-converting enzyme
Journal
MEDICAL ONCOLOGY
Volume 35, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-12-04
DOI
10.1007/s12032-017-1064-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival
- (2017) Taejong Song et al. EUROPEAN JOURNAL OF CANCER PREVENTION
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor angiogenesis revisited: Regulators and clinical implications
- (2017) Roberto Ronca et al. MEDICINAL RESEARCH REVIEWS
- Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions
- (2016) Zhexuan Lin et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Mechanisms of heparanase inhibitors in cancer therapy
- (2016) Benjamin Heyman et al. EXPERIMENTAL HEMATOLOGY
- Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy
- (2016) Ralph D. Sanderson et al. FEBS Journal
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- (2016) Gérard Zalcman et al. LANCET
- The NADPH Oxidase Nox4 mediates tumour angiogenesis
- (2015) V. Helfinger et al. Acta Physiologica
- Low-molecular-weight heparins and cancer: Focus on antitumoral effect
- (2015) Massimo Franchini et al. ANNALS OF MEDICINE
- Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement
- (2015) Sebastian Altenhöfer et al. ANTIOXIDANTS & REDOX SIGNALING
- Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation
- (2015) Todd V. Brennan et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma
- (2015) Vishnu C. Ramani et al. Oncotarget
- Nitric oxide in cancer metastasis
- (2014) Huiwen Cheng et al. CANCER LETTERS
- Lysyl oxidase in cancer research
- (2014) Lara Perryman et al. Future Oncology
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
- (2014) Martin Reck et al. LANCET ONCOLOGY
- Improved Survival with Bevacizumab in Advanced Cervical Cancer
- (2014) Krishnansu S. Tewari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
- (2014) Chun-Jen Liu WORLD JOURNAL OF GASTROENTEROLOGY
- Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models
- (2013) G. Cassinelli et al. BIOCHEMICAL PHARMACOLOGY
- Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales
- (2013) Asmaa E El-Kenawi et al. BRITISH JOURNAL OF PHARMACOLOGY
- Heparanase in inflammation and inflammation-associated cancer
- (2013) Amichay Meirovitz et al. FEBS Journal
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
- (2013) Thomas E Hutson et al. LANCET ONCOLOGY
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- NADPH Oxidases as Regulators of Tumor Angiogenesis: Current and Emerging Concepts
- (2012) Sanja Coso et al. ANTIOXIDANTS & REDOX SIGNALING
- Angiopoietins in angiogenesis
- (2012) Ernesta Fagiani et al. CANCER LETTERS
- Lysyl Oxidase Plays a Critical Role in Endothelial Cell Stimulation to Drive Tumor Angiogenesis
- (2012) A.-M. Baker et al. CANCER RESEARCH
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Arginine-Based Inhibitors of Nitric Oxide Synthase: Therapeutic Potential and Challenges
- (2012) Jan Víteček et al. MEDIATORS OF INFLAMMATION
- Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation
- (2011) Cuneyt K. Buharalioglu et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Concentration- and time-dependent effects of enoxaparin on human adenocarcinomic epithelial cell line A549 proliferation in vitro
- (2011) Walid Abu Arab et al. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
- Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies
- (2011) C. Yoon et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- LMWH Bemiparin and ULMWH RO-14 Reduce the Endothelial Angiogenic Features Elicited by Leukemia, Lung Cancer, or Breast Cancer Cells
- (2011) Alfonso Vignoli et al. CANCER INVESTIGATION
- The HIF-1-Inducible Lysyl Oxidase Activates HIF-1 via the Akt Pathway in a Positive Regulation Loop and Synergizes with HIF-1 in Promoting Tumor Cell Growth
- (2011) F. Pez et al. CANCER RESEARCH
- SST0001, a Chemically Modified Heparin, Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase/Syndecan-1 Axis
- (2011) Joseph P. Ritchie et al. CLINICAL CANCER RESEARCH
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Vascular NADPH Oxidase 1 Blocks Tumor Angiogenesis through a PPARα Mediated Mechanism
- (2011) Sarah Garrido-Urbani et al. PLoS One
- M402, a Novel Heparan Sulfate Mimetic, Targets Multiple Pathways Implicated in Tumor Progression and Metastasis
- (2011) He Zhou et al. PLoS One
- The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model
- (2010) I Debergh et al. BRITISH JOURNAL OF CANCER
- Targeted Inhibition of Inducible Nitric Oxide Synthase Inhibits Growth of Human Melanoma In vivo and Synergizes with Chemotherapy
- (2010) A. G. Sikora et al. CLINICAL CANCER RESEARCH
- Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis
- (2010) Uri Barash et al. FEBS Journal
- Unraveling the Specificity of Heparanase Utilizing Synthetic Substrates
- (2010) Sherket B. Peterson et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Molecular Mediators of Angiogenesis
- (2010) Areck A. Ucuzian et al. Journal of Burn Care & Research
- Expression profiling of ETS and MMP factors in VEGF-activated endothelial cells: Role of MMP-10 in VEGF-induced angiogenesis
- (2010) Sun-Hee Heo et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Pro-inflammatory angiogenesis is mediated by p38 MAP kinase
- (2010) Gangaraju Rajashekhar et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials
- (2010) Ilke Sipahi et al. LANCET ONCOLOGY
- Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment
- (2010) Vivian Barry-Hamilton et al. NATURE MEDICINE
- The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy
- (2009) K. Dredge et al. INVESTIGATIONAL NEW DRUGS
- Influence of Short-term Rosuvastatin Therapy on Endothelial Progenitor Cells and Endothelial Function
- (2009) Matteo Pirro et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- The dual role of thymidine phosphorylase in cancer development and chemotherapy
- (2009) Annelies Bronckaers et al. MEDICINAL RESEARCH REVIEWS
- Endothelial Injury and Repair: A Novel Theory for Atherosclerosis
- (2008) Elmo Mannarino et al. ANGIOLOGY
- A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies
- (2008) Laura Q. M. Chow et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy
- (2008) Masuko Ushio-Fukai et al. CANCER LETTERS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now